Finance

Lists
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹2.283,00
-0,44%
(-10,00) 1D
12 ຕ.ລ., 15 ໂມງ 30 ນາທີ 00 ວິນາທີ GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹2.275,00
High
₹2.293,90
Low
₹2.252,00
Mkt. cap
644,32 ຕື້
Avg. vol.
586,00 ພັນ
Volume
695,53 ພັນ
Dividend
0,22%
Quarterly dividend
₹1,25
Ex-dividend date
3 ຕ.ລ. 2025
P/E ratio
35,85
52-wk high
₹2.537,60
52-wk low
₹1.792,60
EPS
₹63,68
Shares outstanding
0,00
No. of employees
17 ພັນ
Open
₹2.275,00
High
₹2.293,90
Low
₹2.252,00
Mkt. cap
644,32 ຕື້
Avg. vol.
586,00 ພັນ
Volume
695,53 ພັນ
Dividend
0,22%
Quarterly dividend
₹1,25
Ex-dividend date
3 ຕ.ລ. 2025
P/E ratio
35,85
52-wk high
₹2.537,60
52-wk low
₹1.792,60
EPS
₹63,68
Shares outstanding
0,00
No. of employees
17 ພັນ
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16,9 ພັນ
Founded18 ພ.ຈ. 1977
Headquarters-
SectorPharmaceutical industry
Last report
3 ສ.ຫ. 2026
Fiscal period
Q1 2027
₹17,11 / ₹17,30
-1,10%miss
Revenue / Est. (INR)
40,18 ຕື້ / 39,17 ຕື້
+2,60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
60,47 ຕື້
39,01 ຕື້
38,31 ຕື້
40,18 ຕື້
Cost of goods sold
12,65 ຕື້
12,95 ຕື້
13,65 ຕື້
12,46 ຕື້
Cost of revenue
12,65 ຕື້
12,95 ຕື້
13,65 ຕື້
12,46 ຕື້
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,86 ຕື້
8,41 ຕື້
16,49 ຕື້
9,35 ຕື້
Operating expense
25,64 ຕື້
18,90 ຕື້
17,91 ຕື້
21,41 ຕື້
Total operating expenses
38,29 ຕື້
31,85 ຕື້
31,56 ຕື້
33,87 ຕື້
Operating income
22,18 ຕື້
7,15 ຕື້
6,75 ຕື້
6,32 ຕື້
Other non operating income
2,01 ຕື້
444,65 ລ້ານ
-2,72 ຕື້
657,64 ລ້ານ
EBT including unusual items
9,67 ຕື້
5,34 ຕື້
3,88 ຕື້
6,43 ຕື້
EBT excluding unusual items
23,53 ຕື້
7,18 ຕື້
7,61 ຕື້
6,43 ຕື້
Income tax expense
3,57 ຕື້
1,31 ຕື້
864,49 ລ້ານ
1,61 ຕື້
Effective tax rate
36,90%
24,49%
22,29%
24,96%
Other operating expenses
13,37 ຕື້
8,94 ຕື້
-55,65 ລ້ານ
10,33 ຕື້
Net income
6,10 ຕື້
4,03 ຕື້
3,01 ຕື້
4,83 ຕື້
Net profit margin
10,09%
10,34%
7,87%
12,02%
Earnings per share
-
19,21
20,96
17,11
Interest and investment income
-
-
413,36 ລ້ານ
-
Interest expense
-664,63 ລ້ານ
-414,32 ລ້ານ
-426,04 ລ້ານ
-539,97 ລ້ານ
Net interest expenses
-664,63 ລ້ານ
-414,32 ລ້ານ
-12,68 ລ້ານ
-539,97 ລ້ານ
Depreciation and amortization charges
1,41 ຕື້
1,54 ຕື້
1,48 ຕື້
1,73 ຕື້
EBITDA
23,54 ຕື້
7,80 ຕື້
7,80 ຕື້
7,75 ຕື້
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google